Generation and Characterization of a Novel Recombinant Antibody against LMP1-TES1 of Epstein-Barr Virus Isolated by Phage Display

Latent Membrane Protein 1 (LMP1) is a primary target for controlling tumorigenesis in Epstein-Barr virus related malignancies; in this study, we aimed to develop a specific antibody against the TES1 domain of the oncogenic LMP1. We screened a full human naïve Fab phage library against TES1 peptide, which consisted of C terminal-activating regions proximal 44 amino acids. After three rounds of panning, enrichment and testing by phage ELISA and further analyzed by DNA sequencing, we selected a phage clone with the highest affinity to LMP1-TES1 and designated it as htesFab. The positive clone was expressed in Escherichia coli and the purified htesFab was characterized for its binding specificity and affinity to LMP1. ELISA, immunofluorescence and FACS analysis confirmed that htesFab could recognize LMP1 TES1 both in vitro and in LMP1 expressing HNE2-LMP1 cells. Furthermore, MTT assay showed that htesFab inhibited the proliferation of HNE2-LMP1 cells in a dose-dependent manner. In summary, this study reported the isolation and characterization of human Fab, which specifically targets the C terminal region/TES1 of LMP1, and has potential to be developed as novel tool for the diagnosis and therapy of Epstein-Barr virus related carcinoma.

• Publication year

  2013

• Venue

  Viruses

• Publication date

  2013-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/v5041131PMID 23609879PMCID 3705269
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determination of antibodies directed at EBV proteins expressed in both latent and lytic cycles in nasopharyngeal carcinoma.

  2013cited by this paper
• Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin.

  2013cited by this paper
• Current and emerging treatment options for nasopharyngeal carcinoma

  2012cited by this paper
• Contributions of Epstein–Barr Nuclear Antigen 1 (EBNA1) to Cell Immortalization and Survival

  2012cited by this paper
• LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: evidence from a meta-analysis

  2011cited by this paper
• Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.

  2008cited by this paper
• Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.

  2007cited by this paper
• Nasopharyngeal carcinoma: molecular biomarker discovery and progress

  2007cited by this paper
• Puumala virus RNA in cerebrospinal fluid in a patient with uncomplicated nephropathia epidemica.

  2007cited by this paper
• Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma.

  2007cited by this paper
• LMP1 TRAFficking activates growth and survival pathways.

  2007cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Construction of human naïve fab library and characterization of anti-met fab fragment generated from the library

  2005cited by this paper
• Construction and characterization of monoclonal antibodies specific to Epstein-Barr virus latent membrane protein 1.

  2004cited by this paper
• Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation.

  2004cited by this paper
• Epstein-Barr Virus Latent Membrane Protein 1: Structure and Functions

  2003cited by this paper
• LMP1 structure and signal transduction.

  2001cited by this paper
• The cytoplasmic amino-terminus of the Latent Membrane Protein-1 of Epstein-Barr Virus: relationship between transmembrane orientation and effector functions of the carboxy-terminus and transmembrane domain

  2001cited by this paper
• Role of the TRAF Binding Site and NF-κB Activation in Epstein-Barr Virus Latent Membrane Protein 1-Induced Cell Gene Expression

  1998cited by this paper
• Phenotypic knock-out of the latent membrane protein 1 of Epstein–Barr virus by an intracellular single-chain antibody

  1998cited by this paper
• The selection of intracellular antibodies.

  1998cited by this paper
• Localization of the Major NF-κB-activating Site and the Sole TRAF3 Binding Site of LMP-1 Defines Two Distinct Signaling Motifs*

  1997cited by this paper
• Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3

  1997cited by this paper
• Intracellular antibodies (intrabodies) for gene therapy of infectious diseases.

  1997cited by this paper
• Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation

  1996cited by this paper
• Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas.

  1995cited by this paper
• The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.

  1995cited by this paper
• The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues

  1995cited by this paper
• A possible prognostic role of immunoglobulin‐G antibody against recombinant Epstein‐Barr virus BZLF‐1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma

  1994cited by this paper
• Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack

  1993cited by this paper
• Intracellular expression of anti-p21ras single chain Fv fragments inhibits meiotic maturation of xenopus oocytes.

  1993cited by this paper
• All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts

  1993cited by this paper
• Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors

  1991cited by this paper

• Antibody Phage Display Technology for Sensor-Based Virus Detection: Current Status and Future Prospects

  2023cites this paper
• Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

  2023cites this paper
• Insights into intricacies of the Latent Membrane Protein-1 (LMP-1) in EBV-associated cancers.

  2023cites this paper
• Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy

  2021cites this paper
• Use of bacteriophage for discovery of therapeutically relevant antibodies against infectious diseases

  2019cites this paper
• The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

  2018cites this paper
• A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway

  2016cites this paper
• Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display

  2016cites this paper
• Putative phage-display epitopes of the porcine epidemic diarrhea virus S1 protein and their anti-viral activity

  2015cites this paper
• Probing the Sites of Interactions of Rotaviral Proteins Involved in Replication

  2014cites this paper
• ROR1 expression correlated with poor clinical outcome in human ovarian cancer

  2014cites this paper
• Human Monoclonal Antibody-Based Therapy in the Treatment of Invasive Candidiasis

  2013cites this paper